SINGAPORE GENERAL HOSPITAL

Agilent Precision Oncology Summit offers webinars on cancer care precision and immunotherapy, featuring experts like Dr. Timothy Shuen, Dr. Seong-Eui Hong, Asst. Prof. Umberto Malapelle, Prof. Paul Hofman, Dr. Chen Xiu Fen, Dr. Brendan Pang, and Dr. Philippe Taniere.

Madam Chia Lu Ting, 71, regained mobility after using the Bixeps machine at Care Corner Senior Care Centre. Developed in Singapore, Bixeps uses low-energy magnetic fields to improve muscle mass in frail seniors. Clinical trials show significant improvements in muscle strength and pain reduction for patients with knee osteoarthritis. Researchers explore broader benefits, including potential effects on cancer progression.

Singapore General Hospital's AI2D model, developed with DXC Technology, aims to reduce unnecessary antibiotic use and improve prescription accuracy for pneumonia cases, potentially cutting review cases by three times and identifying intervention needs more effectively. The model, trained on 8,000 SGH patients' data, demonstrated 90% accuracy in determining antibiotic necessity, suggesting 40% of prescriptions might be unnecessary. This initiative is crucial as pneumonia accounts for 20% of infections at SGH, with significant healthcare costs and risks of antimicrobial resistance.

Duke-NUS scientists identified an East Asian genetic variation in BIM protein linked to drug resistance in chronic myeloid leukemia, leading to aggressive cancer growth. Their solution involves inhibiting MCL-1 protein, showing promise in killing resistant cancer cells. Published in *Leukemia*, these findings underscore the importance of genetic profiling for effective cancer treatments.

Duke-NUS scientists identified an East Asian genetic variation in BIM that causes drug resistance in chronic myeloid leukaemia, leading to aggressive cancer growth. Their solution involves inhibiting MCL-1 protein, showing promising results in killing resistant cancer cells. This approach highlights the importance of genetic profiling for effective cancer treatments.

Vivance announces successful completion of the next trial phase of its wearable peritoneal dialysis device, Viva Kompact, at Singapore General Hospital. The study results will be presented at ASN Kidney Week 2024 in San Diego, showcasing the device's performance and safety in home use by patients.

Singapore's public healthcare sector sees significant advancements in AI and GenAI, with a focus on preventive care and active ageing. The GovInsider Live Healthcare Day addressed precision medicine, healthtech innovation, data management, and partnerships. Key discussions included the importance of problem-focused innovation, user-friendly and secure GenAI platforms, data sharing for healthcare innovation, community partnerships, and co-designing nudges with users for preventive health.

Singapore researchers uncover mechanisms behind gastric cancer peritoneal metastasis, identify biomarkers, and demonstrate safety of a novel treatment combining PIPAC and immunotherapy in the PIANO trial.